MIST Milestone Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MIST

Price (delayed)

$3.09

Market cap

$103.46M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.38

Enterprise value

$144.61M

Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada ...

Highlights
The EPS is up by 5% YoY
The net income rose by 4.6% YoY
Milestone Pharmaceuticals's revenue has surged by 200% YoY but it has decreased by 25% QoQ
The gross profit has soared by 200% year-on-year but it is down by 25% since the previous quarter
The company's equity has shrunk by 63% YoY and by 29% QoQ
MIST's quick ratio is down by 27% from the previous quarter and by 20% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.milestonepharma.com
Peers: OMGA

Key stats

What are the main financial stats of MIST
Market
Shares outstanding
33.48M
Market cap
$103.46M
Enterprise value
$144.61M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.62
Price to sales (P/S)
29.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.14
Earnings
Revenue
$4.5M
EBIT
-$57.59M
EBITDA
-$57.51M
Free cash flow
-$49.68M
Per share
EPS
-$1.38
Free cash flow per share
-$1.16
Book value per share
$0.85
Revenue per share
$0.1
TBVPS
$2.03
Balance sheet
Total assets
$87.12M
Total liabilities
$58.61M
Debt
$51.03M
Equity
$28.5M
Working capital
$76.68M
Liquidity
Debt to equity
1.79
Current ratio
10.45
Quick ratio
9.52
Net debt/EBITDA
-0.72
Margins
EBITDA margin
-1,278%
Gross margin
100%
Net margin
-1,316.7%
Operating margin
-1,356.8%
Efficiency
Return on assets
-64.1%
Return on equity
-125.3%
Return on invested capital
-62.2%
Return on capital employed
-72.9%
Return on sales
-1,279.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MIST stock price

How has the Milestone Pharmaceuticals stock price performed over time
Intraday
9.19%
1 week
16.6%
1 month
35.53%
1 year
-37.2%
YTD
-21.97%
QTD
-0.32%

Financial performance

How have Milestone Pharmaceuticals's revenue and profit performed over time
Revenue
$4.5M
Gross profit
$4.5M
Operating income
-$61.06M
Net income
-$59.25M
Gross margin
100%
Net margin
-1,316.7%
Milestone Pharmaceuticals's revenue has surged by 200% YoY but it has decreased by 25% QoQ
The gross profit has soared by 200% year-on-year but it is down by 25% since the previous quarter
MIST's net margin has soared by 68% YoY but it is down by 35% QoQ
Milestone Pharmaceuticals's operating margin has soared by 68% YoY but it has decreased by 34% from the previous quarter

Growth

What is Milestone Pharmaceuticals's growth rate over time

Valuation

What is Milestone Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.62
P/S
29.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.14
The EPS is up by 5% YoY
The P/B is 65% higher than the 5-year quarterly average of 2.2 and 39% higher than the last 4 quarters average of 2.6
The company's equity has shrunk by 63% YoY and by 29% QoQ
Milestone Pharmaceuticals's revenue has surged by 200% YoY but it has decreased by 25% QoQ
MIST's P/S is 6% above its last 4 quarters average of 27.9

Efficiency

How efficient is Milestone Pharmaceuticals business performance
Milestone Pharmaceuticals's return on equity has shrunk by 90% YoY and by 27% QoQ
The ROIC has soared by 80% YoY and by 21% QoQ
The ROS has soared by 69% YoY but it is down by 33% QoQ
MIST's ROA is down by 3.9% YoY

Dividends

What is MIST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MIST.

Financial health

How did Milestone Pharmaceuticals financials performed over time
The total assets is 49% greater than the total liabilities
MIST's quick ratio is down by 27% from the previous quarter and by 20% YoY
The current ratio has contracted by 25% from the previous quarter and by 18% YoY
MIST's debt is 79% higher than its equity
The company's equity has shrunk by 63% YoY and by 29% QoQ
MIST's debt to equity is up by 43% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.